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resulted in a more pronounced depletion 
of fibrinogen levels (up to 70%) than a sin-
gle session. Both whole blood and plasma 
viscosity were significantly improved by 
repeated aphereses. During combined fi-
brinogen apheresis and specialized multi-
modal wound care 3 out of 4 patients 
showed improved wound healing. After 
termination of apheresis 1 patient under-
went surgery for diabetic foot syndrome. 
These effects of selective fibrinogen aphe-
resis on microvascular haemodynamics 
may relate not only to sustained lowering 
of fibrinogen, but also to sustained reduc-
tion in the levels of low-density lipoprotein 
cholesterol, C-reactive protein and adhe-
sion molecules.
 There is an urgent need for prospective 
randomized investigations with selective 
fibrinogen apheresis in diseases with al-
tered microvascular haemodynamics to 
corroborate the potential beneficial acute 
or short-term effects observed in small pilot 
studies. Moreover, prospective compari-
sons of this apheresis device with non-se-
 Sir,
 Ramunni et al. [1] showed that a single 
session of selective fibrinogen apheresis 
reduced circulating fibrinogen by 50%. 
They  failed to document significant chang-
es in microvascular haemodynamics by 
 laser Doppler flowmetry in their patients 
affected by various stages of peripheral 
 occlusive arterial disease. Of clinical rele-
vance, symptomatic improvement was im-
pressive, with both total and pain-free 
walking distance increasing significantly.
 Short-term improvement in delayed 
wound healing, another clinical symptom 
of severe impairment of microcirculation, 
has been reported for few patients with di-
abetic foot syndrome or patients with isch-
emic skin lesions  [2] . Our group performed 
repetitive treatments with selective fibrin-
ogen adsorption (TheraSorb Technology, 
Plasma Select AG, Teterow, Germany) for 
4 weeks in 4 diabetic patients  [3] . Treat-
ments were scheduled on days 1, 2, 4, 6, 8, 
10, 13, 16, 19, 22, 25, and 28. No clinical 
side effects of the procedure were observed 
during 46 sessions. Multiple treatments 
 Published online: January 14, 2008 
 Prof. Dr. H. Schiff l 
 University of Munich, Department of Internal Medicine  
 Ziemssenstrasse 1 
 DE–80336 Munich (Germany) 
 Tel. +49 89 5160 8397, Fax +49 89 5705 727, E-Mail hschiff l@hotmail.com 
 © 2008 S. Karger AG, Basel
0253–5068/07/0256–0515$23.50/0 
 Accessible online at:
www.karger.com/bpu 
lective plasma exchange or low-density li-
poprotein apheresis are lacking. This places 
considerable constraints on a more wide-
spread application of the costly and time-
consuming selective fibrinogen aphe resis.
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 Sir,
 I agree with the author of the letter on 
the necessity of carrying out multicenter 
studies, numerically suitable, with the ob-
jective of confirming the efficiency of 
apheresis procedures in the treatment of 
microcirculation disorders.
 However, I do not think that the use of 
highly selective apheresis, such as fibrino-
gen apheresis, should be considered an ex-
pensive or time-consuming event. On the 
contrary, the possibility of withdrawing 
specific molecules from the bloodstream 
allows for the capacity to investigate the 
pathological process at the base of the vas-
cular damage, which is certainly preclud-
ed from the plasma exchange, whose com-
plete absence of selectivity in the elimina-
tion of substances does not provide any 
useful information on the matter. In our 
article, to which the author of the letter 
 refers, our aim has been to investigate, 
among other factors, some markers of the 
endothelial activation.
 One possibility in this sense also de-
rives from double filtration plasmaphere-
sis, a semi-selective procedure to use and 
compare with decidedly selective aphere-
sis in the treatment of peripheral arterial 
disease. Only the comparison between
the efficiency of low-density lipoprotein 
apheresis and fibrinogen apheresis on the 
one hand and double filtration plasma-
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pheresis on the other will allow us to better 
understand the pathogenesis of microcir-
culation disturbances, helping us to choose 
the most efficient procedure for the treat-
ment of our patients. In this view, the 
methodologies of selective apheresis, be-
sides the strategies of a therapeutic ap-
proach, are to be considered real laborato-
ries of in vivo investigation, which help us 
to understand the role of individual mol-
ecules in the development of vascular pa-
thologies. Consequently, instead of being 
dismissed for the costs or workload, they 
should be used on a greater scale, with the 
objective of clarifying their correct utiliza-
tion. 
